The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 13, 2020

Filed:

Apr. 25, 2018
Applicants:

Agenus Inc., Lexington, MA (US);

Memorial Sloan-kettering Cancer Center, New York, NY (US);

Ludwig Institute for Cancer Research Ltd., Zurich, CH;

Inventors:

Ana M. Gonzalez, Cambridge, MA (US);

Nicholas S. Wilson, Somerville, MA (US);

Dennis J. Underwood, Jamaica Plain, MA (US);

Volker Seibert, Lörrach, DE;

Olivier Léger, Saint-Sixt, FR;

Marc Van Dijk, Bilthoven, NL;

Roberta Zappasodi, New York, NY (US);

Taha Merghoub, Jersey City, NJ (US);

Jedd David Wolchok, New York, NY (US);

David Schaer, Mamaroneck, NY (US);

Gerd Ritter, New York, NY (US);

Takemasa Tsuji, Williamsville, NY (US);

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); G01N 33/50 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 35/17 (2013.01); C07K 16/2809 (2013.01); G01N 33/502 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/70578 (2013.01); Y02A 50/386 (2018.01);
Abstract

The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.


Find Patent Forward Citations

Loading…